Review on Psoriasis Disease
DOI:
https://doi.org/10.22270/ajprd.v10i1.1084Keywords:
Psoriasis, Phytopharmaceuticals, keratinocytes.Abstract
Psoriasis is an autoimmune disease characterised by the proliferation of keratinocytes throughout time. On average, it affects 2-5 percent of the world's population. Psoriasis treatment remains difficult due to a variety of factors influencing treatment, including patient compliance and adherence to therapy, delicate patient profiles, psychological factors, and skin as a barrier to topical delivery. Pathophysiology, triggering factors, and clinical categorization were covered in the first section. Topical, oral, biological, parenteral therapy, phototherapy, and phytopharmaceuticals were all covered in the second section.
Downloads
Download data is not yet available.
References
1. Harman Bakshi, Manju Nagpa, Manjinder Singh, Gitika Arora Dhingra and Geeta Aggarwal, “Treatment of Psoriasis: A Comprehensive Review of Entire Therapies”, Chitkara College of Pharmacy, Chitkara University, Punjab, India; 2NCRD’S Sterling Institute of Pharmacy Navi Mumbai, India; 3Delhi Pharmaceutical Sciences and Research University, New Delhi-110017, India
2. Christophers, E. Psoriasis—Epidemiology and clinical spectrum. Clin. Exp. Dermatol. 2001, 26, Page No. 314–320.
3. Parisi, R.; Symmons, D.P.; Griffiths, C.E.; Ashcroft, D.M. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol. 2013, 133, Page No. 377–385.
4. Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int. J. Dermatol. 1996, 35, Page No. 633–639.
5. Rachakonda, T.D.; Schupp, C.W.; Armstrong, A.W. Psoriasis prevalence among adults in the United States. J. Am. Acad. Dermatol. 2014, 70, Page No. 512–516.
6. Danielsen, K.; Olsen, A.O.; Wilsgaard, T.; Furberg, A.S. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br. J. Dermatol. 2013, 168, Page No. 1303–1310.
7. Papola Vibhooti , Dr. Kumar Ashok, Sah Shilpa, Nautiyal Himani, “Fight Psoriasis Naturally Through Ayurveda”, Shri Dev Bhoomi, Institute of Education Science & Technology, Dehradun, Uttarakhand, India.
8. Nestle F O, Kaplan D H, Barker J, “Psoriasis”. The New England Journal of Medicine. 361(5):July 2009, Page No. 496-509.
9. Rendon A, Schäkel K, "Psoriasis Pathogenesis and Treatment.International Journal of Molecular Sciences. 20 (6): March 2019, Page No. 1475.
10. Parrish L, “Psoriasis: symptoms, treatment, and itsimpacton quality of life”, British Journal of Community Nursing, Nov. 2012
11. Palfreeman A C, McNamee K E, McCann F E (March 2013). "New developments in the management of psoriasis and psoriatic arthritis: a focus on a premilast "Drug Design, Development and Therapy.7: Page No. 201-10.
12. Cedeno-Laurent F, Gómez - Flores M, Mendez N, Ancer-Rodríguez J, Bryant J L, Gaspari A A, Trujillo J R. "New insights into HIV-1-primary skin disorders ". Journal of the International AIDS Society,January 2011, 14 (5): Page No. 5.
13. Baliwag J, Barnes D H, Johnston A. "Cytokines in psoriasis", Cytokine. Skin Disease, Immune Response and Cytokines. 73 (2): 34,June 2015, Page No. 2-5.
14. Larsabal M,Ly S , sbidian e, moyalbarracco m, dauendorffer JN , dupin n, Richard MA , Chosidow O, Beylot-Barry M,
15. Papola Vibhooti, Dr. Kumar Ashok, Sah Shilpa, Nautiyal Himani, “Fight Psoriasis Naturally through Ayurveda” Indo American Journal of Pharmaceutical Research, 2016 Shri Dev Bhoomi Institute of Education Science & Technology, Dehradun, Uttarakhand, India.
16. Dogra S, Kaur I. Childhood psoriasis. Indian J Dermatol Venereol Leprol 2010; 76:Page No. 357-65.
17. Thami GP, Sarkar R. Coal tar: Past, present and future. Clin Exp Dermatol 2002; 27:Page No. 99- 103.
18. NICE. The assessment and management of psoriasis. CG153. 2012.
19. Kuijpers AL, van Dooren-Greebe JV, van de Kerkhof PC. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis. Dermatology 1997; 194: Page No. 88-90.
20. Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006; 154:1169-Page No. 74.
21. Brownell I, Strober BE. Folate with methotrexate: big benefit, questionable cost. Br J Dermatol 2007;Page No. 157-213.
22. Laharie D, Terrebonne E, Vergniol J, Chanteloup E, Chabrun E, Couzigou P et al. The liver and methotrexate. Gastroenterol Clin Biol, 2008;32:Page No. 134-42.
23. Colombo MD, Cassano N, Bellia G. Cyclosporineregimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches, Scientific World Journal 2013;13:Page No. 1-11.
24. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-Page No. 85.
25. Treumer F, Zhu K, Glaser R et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121: Page No. 1383–8.
26. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 1999; 141: Page No. 424–9.
27. Wong T, Hsu L, Liao W. Phototherapy in psoriasis: a review of mechanisms of action. J Cutan Med Surg 2013; 17(1): Page No. 6-12.
28. Roelandts R. The history of phototherapy: something new under the sun? J Am Acad Dermatol. 2002; 46: Page No. 926-30.
29. Agnivesha, Chikitsasthana 7: 11-12, Hindi commentary by Brahmanand Tripathi, Charak Samhita, Varanasi, Chaukhamba Surbhaharti Prakashana; 2011. Page No. 302.
30. Agnivesha, Chikitsasthana 7: 21, Hindi commentary by Brahmanand Tripathi, Charak Samhita, Varanasi, Chaukhamba Surbhaharti Prakashana; 2011. Page No. 305.
31. Baldeep Kour,Psoriasis Treatment in Ayurveda & Panchakarma Rajiv Gandhi University of Health Sciences, India, Volume 7 Issue 2 - 2017
32. The Ayurvedic Pharmacopoeia of India, Part-1, Govt.of India Ministry of Health &Family Welfare dept.of Ayush. New Delhi; Vol-3, Page No. 113.
33. The Ayurvedic Pharmacopoeia of India, Part-1, Govt.of India Ministry of Health & Family Welfare dept.of Ayush.New Delhi; Vol-2, Page No. 36.
34. The Ayurvedic Pharmacopoeia of India, Part-1, Govt.of India Ministry of Health & Family Welfare dept.of Ayush.New Delhi;Vol-1, Page No. 8.
35. G.P.Gune, (Aushadhi Gundharma shatra. part-2, kalpa no 10, reprint 2005, Page No.208.
36. Gune G.P., (Aushadhi Gundharma shatra. part-3, kalpa no 66, reprint 2005, Page No. 395.
37. Rasatantrasara va sidhaprayog sangraha by krushna Gopal Bhawan, pratham khanda, kharaliya rasayan – Page No. 225, 226.
38. The Ayurvedic Pharmacopoeia of India, Part-1, Govt.of India Ministry of Health & Family Welfare dept.of AYUSH.New Delhi; vol-2, Page No. 84.
39. The Ayurvedic pharmacopoeia of india-part-1, gov.of india ministry of health & family welfare dep.of AYUSH.new delhi; vol-2, Page No. 136.
40. Brhamananda Tripathi, Charak Samhita, Maharshi Charak, Chikitsa-stankushta chikitsa adhya: 1st Ed., Chapter 7,Verse no.99, Varanasi: Chukhambha Prakashan, 2011; Page No.320.
2. Christophers, E. Psoriasis—Epidemiology and clinical spectrum. Clin. Exp. Dermatol. 2001, 26, Page No. 314–320.
3. Parisi, R.; Symmons, D.P.; Griffiths, C.E.; Ashcroft, D.M. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol. 2013, 133, Page No. 377–385.
4. Gibbs, S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int. J. Dermatol. 1996, 35, Page No. 633–639.
5. Rachakonda, T.D.; Schupp, C.W.; Armstrong, A.W. Psoriasis prevalence among adults in the United States. J. Am. Acad. Dermatol. 2014, 70, Page No. 512–516.
6. Danielsen, K.; Olsen, A.O.; Wilsgaard, T.; Furberg, A.S. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br. J. Dermatol. 2013, 168, Page No. 1303–1310.
7. Papola Vibhooti , Dr. Kumar Ashok, Sah Shilpa, Nautiyal Himani, “Fight Psoriasis Naturally Through Ayurveda”, Shri Dev Bhoomi, Institute of Education Science & Technology, Dehradun, Uttarakhand, India.
8. Nestle F O, Kaplan D H, Barker J, “Psoriasis”. The New England Journal of Medicine. 361(5):July 2009, Page No. 496-509.
9. Rendon A, Schäkel K, "Psoriasis Pathogenesis and Treatment.International Journal of Molecular Sciences. 20 (6): March 2019, Page No. 1475.
10. Parrish L, “Psoriasis: symptoms, treatment, and itsimpacton quality of life”, British Journal of Community Nursing, Nov. 2012
11. Palfreeman A C, McNamee K E, McCann F E (March 2013). "New developments in the management of psoriasis and psoriatic arthritis: a focus on a premilast "Drug Design, Development and Therapy.7: Page No. 201-10.
12. Cedeno-Laurent F, Gómez - Flores M, Mendez N, Ancer-Rodríguez J, Bryant J L, Gaspari A A, Trujillo J R. "New insights into HIV-1-primary skin disorders ". Journal of the International AIDS Society,January 2011, 14 (5): Page No. 5.
13. Baliwag J, Barnes D H, Johnston A. "Cytokines in psoriasis", Cytokine. Skin Disease, Immune Response and Cytokines. 73 (2): 34,June 2015, Page No. 2-5.
14. Larsabal M,Ly S , sbidian e, moyalbarracco m, dauendorffer JN , dupin n, Richard MA , Chosidow O, Beylot-Barry M,
15. Papola Vibhooti, Dr. Kumar Ashok, Sah Shilpa, Nautiyal Himani, “Fight Psoriasis Naturally through Ayurveda” Indo American Journal of Pharmaceutical Research, 2016 Shri Dev Bhoomi Institute of Education Science & Technology, Dehradun, Uttarakhand, India.
16. Dogra S, Kaur I. Childhood psoriasis. Indian J Dermatol Venereol Leprol 2010; 76:Page No. 357-65.
17. Thami GP, Sarkar R. Coal tar: Past, present and future. Clin Exp Dermatol 2002; 27:Page No. 99- 103.
18. NICE. The assessment and management of psoriasis. CG153. 2012.
19. Kuijpers AL, van Dooren-Greebe JV, van de Kerkhof PC. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis. Dermatology 1997; 194: Page No. 88-90.
20. Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006; 154:1169-Page No. 74.
21. Brownell I, Strober BE. Folate with methotrexate: big benefit, questionable cost. Br J Dermatol 2007;Page No. 157-213.
22. Laharie D, Terrebonne E, Vergniol J, Chanteloup E, Chabrun E, Couzigou P et al. The liver and methotrexate. Gastroenterol Clin Biol, 2008;32:Page No. 134-42.
23. Colombo MD, Cassano N, Bellia G. Cyclosporineregimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches, Scientific World Journal 2013;13:Page No. 1-11.
24. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-Page No. 85.
25. Treumer F, Zhu K, Glaser R et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121: Page No. 1383–8.
26. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 1999; 141: Page No. 424–9.
27. Wong T, Hsu L, Liao W. Phototherapy in psoriasis: a review of mechanisms of action. J Cutan Med Surg 2013; 17(1): Page No. 6-12.
28. Roelandts R. The history of phototherapy: something new under the sun? J Am Acad Dermatol. 2002; 46: Page No. 926-30.
29. Agnivesha, Chikitsasthana 7: 11-12, Hindi commentary by Brahmanand Tripathi, Charak Samhita, Varanasi, Chaukhamba Surbhaharti Prakashana; 2011. Page No. 302.
30. Agnivesha, Chikitsasthana 7: 21, Hindi commentary by Brahmanand Tripathi, Charak Samhita, Varanasi, Chaukhamba Surbhaharti Prakashana; 2011. Page No. 305.
31. Baldeep Kour,Psoriasis Treatment in Ayurveda & Panchakarma Rajiv Gandhi University of Health Sciences, India, Volume 7 Issue 2 - 2017
32. The Ayurvedic Pharmacopoeia of India, Part-1, Govt.of India Ministry of Health &Family Welfare dept.of Ayush. New Delhi; Vol-3, Page No. 113.
33. The Ayurvedic Pharmacopoeia of India, Part-1, Govt.of India Ministry of Health & Family Welfare dept.of Ayush.New Delhi; Vol-2, Page No. 36.
34. The Ayurvedic Pharmacopoeia of India, Part-1, Govt.of India Ministry of Health & Family Welfare dept.of Ayush.New Delhi;Vol-1, Page No. 8.
35. G.P.Gune, (Aushadhi Gundharma shatra. part-2, kalpa no 10, reprint 2005, Page No.208.
36. Gune G.P., (Aushadhi Gundharma shatra. part-3, kalpa no 66, reprint 2005, Page No. 395.
37. Rasatantrasara va sidhaprayog sangraha by krushna Gopal Bhawan, pratham khanda, kharaliya rasayan – Page No. 225, 226.
38. The Ayurvedic Pharmacopoeia of India, Part-1, Govt.of India Ministry of Health & Family Welfare dept.of AYUSH.New Delhi; vol-2, Page No. 84.
39. The Ayurvedic pharmacopoeia of india-part-1, gov.of india ministry of health & family welfare dep.of AYUSH.new delhi; vol-2, Page No. 136.
40. Brhamananda Tripathi, Charak Samhita, Maharshi Charak, Chikitsa-stankushta chikitsa adhya: 1st Ed., Chapter 7,Verse no.99, Varanasi: Chukhambha Prakashan, 2011; Page No.320.
Published
2022-02-15
How to Cite
Malpure, P. S., Kadam, G. R., Chitte, S. D., & Kale, G. S. (2022). Review on Psoriasis Disease. Asian Journal of Pharmaceutical Research and Development, 10(1), 55–63. https://doi.org/10.22270/ajprd.v10i1.1084
Issue
Section
Review Articles
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.